We characterized the incidence of central nervous system (CNS) metastases after treatment with trastuzumab emtansine (T-DM1) versus capecitabine-lapatinib (XL), and treatment efficacy among patients with pre-existing CNS metastases in the phase III EMILIA study.
for the treatment of CNS metastases across breast cancer subtypes, but are associated with high rates of intracranial progression [10] [11] [12] .
The efficacy of systemic therapy may be limited by an inability to access the brain, drug efflux pumps that may exclude cytotoxic and HER2-directed agents, and acquired resistance to prior treatment regimens [13, 14] . Accumulating evidence, however, suggests a potential role for HER2-directed therapy in patients with CNS metastases secondary to HER2-positive MBC. In several prospective trials, lapatinib-as a single agent or combined with capecitabine (XL)-demonstrated some activity in HER2-positive CNS metastases [15] [16] [17] . It has been proposed that switching patients with treated CNS metastases to XL may prevent further CNS progression and improve patient outcomes [18] . Retrospective studies have indicated that use of trastuzumab, a humanized monoclonal antibody targeting HER2, is associated with an increased time to development of brain metastases and improved survival after the development of brain metastases [4, 5, [19] [20] [21] . Although trastuzumab is generally believed to be too large to cross the blood-brain barrier, a recent positron emission tomography imaging study using 89 Zrtrastuzumab in patients with HER2-positive MBC has shown that trastuzumab can access brain metastases, possibly due to a compromised blood-brain barrier [22] .
Trastuzumab emtansine (T-DM1), an antibody drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable linker, facilitates intracellular delivery of DM1 to HER2-overexpressing tumor cells, resulting in inhibition of microtubule function and cell death [23] . Like trastuzumab, T-DM1 inhibits HER2 signaling, prevents HER2 shedding, and induces antibody-dependent cellular cytotoxicity [24] . T-DM1 is approved in several countries as a single agent for HER2-positive MBC previously treated with trastuzumab and a taxane. In the phase III EMILIA trial, T-DM1 significantly prolonged median progression-free survival [PFS; hazard ratio (HR) = 0.65; P < 0.001; 9.6 versus 6.4 months] and median overall survival (OS; HR = 0.68; P < 0.001; 30.9 versus 25.1 months), with less grade ≥3 toxicity, compared with XL in patients with previously treated HER2-positive locally advanced breast cancer (LABC) or MBC [25] . Here, we present the rates of CNS progression in the overall EMILIA population, as well as efficacy and safety results from the subgroup of EMILIA participants with pre-existing, treated/stable CNS metastases. methods study design and patients EMILIA (NCT00829166) is a multicenter, randomized, open-label, phase III trial in which 991 patients with documented progression of HER2-positive, unresectable, LABC or MBC previously treated with trastuzumab and a taxane were randomized 1 : 1 to T-DM1 or XL (supplementary Figure S1 , available at Annals of Oncology online). Eligible patients had centrally confirmed HER2-positive tumor status, measurable and/or nonmeasurable disease, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. Prior exposure to T-DM1, lapatinib, or capecitabine was not permitted.
Patients received T-DM1 3.6 mg/kg i.v. every 21 days or capecitabine 1000 mg/m 2 orally twice-daily on days 1-14 of each 21-day cycle and lapatinib 1250 mg orally once-daily on days 1-21. Treatment continued until progressive disease (PD) or unacceptable toxicity. PFS and OS benefits in favor of T-DM1 were demonstrated in the intent-to-treat (ITT) population [25] . Patients in the XL arm were allowed to receive post-progression treatment with T-DM1 after a survival benefit in favor of T-DM1 was demonstrated in the ITT population [25] . Tumor assessments of extracranial sites were carried out by investigators and an independent review committee (IRC) at baseline and every 6 weeks thereafter, using computed tomography (CT), bone scans, X-rays, and magnetic resonance imaging (MRI) as indicated, until investigator-assessed PD; a final assessment was required 6 weeks post-progression. Once PD was reported, patients were followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination. Information on subsequent anticancer therapies after study treatment discontinuation was collected.
The primary results of EMILIA, including detailed eligibility criteria and methodology, have been published [25] . As with the primary analysis [25] , a 14 January 2012 cutoff was used for PFS and time-to-symptom progression analyses. A 31 July 2012 data cutoff was used for the OS and safety analyses presented here.
The protocol was approved by the relevant institutional review boards/ ethics committees. The trial was conducted in accordance with the Declaration of Helsinki, Good Clinical Practices, and applicable local laws. Patients provided written informed consent.
CNS metastases
All patients underwent brain MRI or CT at screening. Follow-up scans were carried out as clinically indicated, but were not mandated. Patients with CNS metastases that were untreated, were symptomatic, or required therapy to control symptoms ≤2 months before randomization were excluded, as were patients with CNS-only disease. Patients with asymptomatic CNS metastases previously treated with radiotherapy were eligible to enroll 14 days after last radiotherapy treatment.
Patients with treated, asymptomatic CNS metastases at baseline or who developed CNS metastases on-study were identified retrospectively using tumor assessment data from the IRC; this analysis was exploratory and not prespecified. Kaplan−Meier methodology was used to estimate median PFS, OS, and time-to-symptom progression in the subgroup with baseline CNS metastases. These end points are defined in the supplementary Material, available at Annals of Oncology online. Stratified Cox proportional hazards models were used to estimate HRs and corresponding 95% confidence intervals (CIs); P-values were calculated via a stratified log-rank test. No correction for multiple testing was carried out in these exploratory analyses. Strata were world region, prior chemotherapy regimen for LABC/MBC, and presence of visceral disease. A multivariate Cox regression model, which adjusted for potential confounding factors, was also used to estimate HRs for PFS and OS. The model included world region, prior chemotherapy regimens for LABC/MBC, presence of visceral disease, age, race, number of disease sites, prior anthracycline therapy, baseline ECOG PS, estrogen receptor and progesterone receptor status, baseline disease measurability, menopausal status, prior anticancer therapy, prior trastuzumab therapy, and HER2 status by fluorescence in situ hybridization and immunohistochemistry. XL. Baseline characteristics were generally similar between patients with baseline CNS metastases and the ITT population, except that patients with CNS metastases were more likely to have an ECOG PS of 1 (versus 0), ≥3 sites of disease, and visceral disease involvement (Table 1 ). Within the subset of patients with baseline CNS metastases, baseline characteristics were similar between treatment arms, although there was a higher proportion of Asian patients (race and region) and patients with hormone receptor-positive cancers in the T-DM1 arm and a higher proportion of patients who received wholebrain radiotherapy (versus localized radiotherapy) in the XL arm.
Patients with baseline CNS metastases randomized to T-DM1 had a longer treatment duration and higher dose intensity compared with patients randomized to XL (supplementary Table S1 , available at Annals of Oncology online). The percentage of patients with CNS metastases at baseline who required a dose reduction of T-DM1 versus lapatinib was similar [23.3% (10/43) versus 24.5% (12/49)]; however, 49.0% (24/49) of patients required a dose reduction of capecitabine. Of the 10 patients requiring a dose reduction of T-DM1, dose was reduced to 3.0 mg/kg in 8. A description of the anticancer therapies used in the post-progression setting is provided supplementary Table S3 , available at Annals of Oncology online.
efficacy
Although the absolute risk of CNS progression on study was higher in patients with baseline CNS metastases, the percentage of patients with CNS progression on study was similar for the two regimens, regardless of whether patients had pre-existing CNS metastases at baseline. Among those patients without CNS metastases at baseline, 2.0% (9/450) and 0.7% (3/446) developed CNS progression on study in the T-DM1 and XL arms, respectively. Among the 95 patients with CNS metastases at baseline, 22.2% (10/45) and 16.0% (8/50), respectively, developed CNS progression on study.
In the subgroup of patients with baseline CNS metastases, the estimated median PFS for T-DM1 (5.9 months) was similar to that for XL (5.7 months) per IRC assessment (HR = 1.00; 95% CI 0.54-1.84; P = 1.000) ( Figure 1A ). For comparison, median PFS among all randomized EMILIA participants was 9.6 months in the T-DM1 arm and 6.4 months in the XL arm (HR = 0.65; P < 0.001) [25] . Multivariate analysis of IRC-assessed PFS, which adjusted for baseline risk factors, was consistent with the unadjusted analysis in this subgroup (HR = 0.97; P > 0.908). Investigatorassessed median PFS also appeared similar for the T-DM1 and XL arms in patients with CNS metastases at baseline (HR = 0.78; 95% CI 0.44-1.39; P = 0.392; 5.9 versus 4.6 months) ( Figure 1B) . A significant difference in median time-to-symptom progression was not observed between treatment arms (HR = 0.70; 95% CI 0.33-1.48; P = 0.338; 7.2 versus 5.5 months, respectively) ( Figure 1C) .
At data cutoff, there was a significant difference in OS between treatments in the subgroup of patients with baseline CNS metastases (HR = 0.38; 95% CI 0.18-0.80; P = 0.008) ( Figure 1D ). The estimated median OS was 26.8 months with T-DM1 versus 12.9 months with XL. This finding was consistent with the OS result among all randomized patients in EMILIA, with a median OS of 30.9 months in the T-DM1 arm and 25.1 months in the XL arm (HR = 0.68; P < 0.001) [25] . Multivariate analysis, which adjusted for baseline risk factors, showed a similar improvement in OS with T-DM1 relative to XL, as in the unadjusted analysis (HR = 0.28; P < 0.001).
safety
No new safety signals were observed in patients with baseline CNS metastases (T-DM1, n = 43; XL, n = 49), with the safety profiles of both treatments being generally similar to those reported in the overall treated population. In patients with CNS metastases at baseline, grade ≥3 adverse events (AEs; 48.8% versus 63.3%), serious AEs (18.6% versus 26.5%), AEs leading to treatment discontinuation (2.3% versus 12.2%), any-grade diarrhea (18.6% versus 79.6%), and any-grade hand-foot syndrome (2.3% versus 46.9%) occurred more frequently with XL. In contrast, a higher incidence of any-grade hepatotoxicity (25.6% versus 14.3%), any-grade thrombocytopenia (32.6% versus 4.1%), and any-grade hemorrhage (27.9% versus 12.2%) was reported with T-DM1 (supplementary Table S2 , available at Annals of Oncology online). Two patients experienced cerebral hemorrhage (grade 3 subdural hemorrhage, grade 2 extradural hemorrhage); both were assigned to XL.
discussion
An important consideration when administering systemic treatment of HER2-positive MBC is the potential for CNS progression, given that the CNS may act as a sanctuary for metastatic disease in the context of a preserved blood-brain barrier [14] . This retrospective, exploratory analysis characterized the incidence of CNS progression following treatment with T-DM1 or XL in patients with HER2-positive MBC in the EMILIA study. The percentage of patients with CNS progression on-study was similar between the two treatments, irrespective of whether patients had baseline CNS metastases. These findings are consistent with the results of a prospective phase III study in patients with HER2-positive MBC without CNS metastases, which showed that the incidence of CNS metastases as the site of first relapse [odds ratio (OR) = 0.65; P = 0.360] and at any time point (OR = 1.14, P = 0.865) was similar whether a patient received trastuzumab plus capecitabine or XL [26] . In the current analysis, the low incidence of CNS progression in patients without CNS metastases at baseline may be due, in part, to continued HER2 tumor suppression, which potentially contributes to delayed development of CNS metastases by controlling extracranial disease [27] [28] [29] . Moreover, the permeability of the blood-brain barrier may be increased with the development of CNS metastases, thereby facilitating drug uptake and allowing greater local control [22, 30] .
We also evaluated the efficacy and safety of T-DM1 versus XL in patients with treated, asymptomatic CNS metastases at baseline. Similar to the EMILIA ITT population [25] , T-DM1 was associated with significantly improved OS compared with XL in this subgroup. Although median PFS and time-to-symptom progression tended to favor T-DM1, these outcomes did not differ significantly between treatments. The reasons for the discrepancy in OS and PFS findings in patients with baseline CNS metastases are unclear. Possible explanations include the small subgroup size and asymmetry in the use and type of subsequent anticancer therapies after study treatment discontinuation. Alternatively, the effect of T-DM1 in improving OS may have stemmed from improved control of systemic extracranial disease and/or other factors. Moreover, brain metastases, which can compromise the integrity of the blood-brain barrier, could have facilitated the entry of T-DM1 into the CNS compartment [22] . The safety profiles of T-DM1 and XL in patients with baseline CNS metastases were consistent with those in the EMILIA primary analysis [25] , with T-DM1 associated with a lower incidence of grade ≥3 and serious AEs. Importantly, the incidence of hemorrhage following T-DM1 was comparable between the subgroup of patients with CNS metastases at baseline and the overall safety population. No new safety signals were identified in this exploratory subgroup.
When considering the clinical implications of the current analysis, it is important to understand the benefit-to-risk ratio for distinct subpopulations of patients with HER2-positive MBC: those without detectable CNS metastases; those with treated, asymptomatic CNS metastases; and those with progressive, symptomatic metastases. In this subgroup analysis, patients without detectable CNS metastases at baseline and those with treated, asymptomatic CNS metastases experienced significantly longer survival with T-DM1 compared with XL, with no major differences in the rate of CNS progression between treatments. Our results, therefore, support use of T-DM1, after prior therapy with a taxane and trastuzumab, in both patient subsets.
The current analysis is limited in that the evaluation of CNS metastases was retrospective and exploratory, and the sample size was relatively small ( potentially resulting in an overadjusted multivariate model). Additionally, while brain imaging was reviewed by the IRC, there was no mandatory or prespecified imaging requirement except at screening, potentially resulting in an underestimate of the incidence of CNS progression in both treatment arms. Moreover, there may have been bias toward a lower incidence of CNS progression in the XL arm since the ITT population had shorter PFS, decreasing the possibility of detecting CNS progression that may have occurred after the first site of progression. Importantly, since patients with progressive CNS metastases were excluded, the study was not able to test whether T-DM1 can induce CNS tumor shrinkage or stabilization in the setting of untreated or active CNS disease. A recently published case report suggests that T-DM1 may be active in the brain [31] .
In conclusion, our analysis suggests that T-DM1 may confer a survival advantage over XL in patients with treated, asymptomatic CNS metastases and previously treated HER2-positive MBC, without increasing the risk for CNS progression. These findings challenge the concept that patients with stable CNS disease should be switched to lapatinib-based therapy after localized treatment to prevent further CNS progression or to improve clinical outcomes. We acknowledge that these data are hypothesisgenerating; however, we believe they warrant prospective study into the activity of HER2-directed therapies in patients with CNS metastases stemming from HER2-positive MBC.
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